Announcement on Change of Sponsor Representative for Continuous Supervision
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Change of Sponsor Representative for Continuous Supervision
Filed with SSE · · 2 pages · Chinese
Release
Zhejiang East Asia Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang East Asia Pharmaceutical
- Announcement on Postponement of Investment Projects Financed by Funds Raised from Convertible Corporate Bonds
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Obtaining Registration Certificate for Drug Substance of Trimebutine from the Republic of Korea
- Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
- Announcement on Change of Accounting Policies
Later from Zhejiang East Asia Pharmaceutical
- Announcement on Obtaining the Drug Registration Certificate for Levofloxacin Tablets
- Announcement on 2025 Follow-up Rating Results of Convertible Corporate Bonds Issued to Non-specific Objects
- Announcement on Resolutions of the 8th Meeting of the 4th Board of Supervisors
- Announcement on Wholly-owned Subsidiary Obtaining CNAS (China National Accreditation Service for Conformity Assessment) Laboratory Accreditation Certificate
- Semi-annual Earnings Preannouncement for 2025
Follow Zhejiang East Asia Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang East Asia Pharmaceutical